Anxiety Labs and Next Steps: What to Test and When to Act

Why Anxiety Deserves a Lab Workup

Anxiety disorders affect an estimated 301 million people worldwide, making them the most common class of mental health conditions according to the World Health Organization [1]. Yet many patients and clinicians skip the laboratory evaluation and move straight to psychiatric treatment. That is a mistake when a treatable medical condition could be driving the symptoms.

Medical Conditions That Mimic Anxiety

Hyperthyroidism is the most well-known medical mimic of anxiety. Excess thyroid hormone triggers tachycardia, tremor, heat intolerance, and a subjective feeling of dread that is clinically indistinguishable from panic disorder. A 2019 meta-analysis published in JAMA Psychiatry found that patients with hyperthyroidism had a 1.6-fold increased risk of anxiety disorders compared to euthyroid controls [2]. Other conditions that can present with anxiety-like symptoms include pheochromocytoma (episodic catecholamine surges), Cushing syndrome (cortisol excess), hyperparathyroidism (calcium-mediated neurotoxicity), and iron-deficiency anemia [3].

The 10% Rule

Estimates vary, but clinical reviews from the Cleveland Clinic and Mayo Clinic suggest that roughly 5-10% of patients who present to primary care with anxiety have an underlying medical cause that blood work can identify [4]. That number rises in patients over 40, in those with no prior psychiatric history, and in anyone whose anxiety appeared suddenly without a clear psychosocial trigger.

A simple blood draw can save months of trial-and-error psychiatric prescribing. The cost of a basic lab panel is low relative to the cost of misdiagnosis.

The Core Anxiety Lab Panel

The goal of laboratory testing is not to "diagnose anxiety." No blood test can do that. The goal is to rule out organic causes that would change management entirely. The following panel covers the highest-yield tests recommended by UpToDate and the American Academy of Family Physicians [5].

TSH and Free T4

Thyroid-stimulating hormone (TSH) and free thyroxine (free T4) are the single most important labs in an anxiety workup. A suppressed TSH with elevated free T4 confirms hyperthyroidism. Subclinical hyperthyroidism (low TSH, normal free T4) can also produce anxiety symptoms, particularly in women during perimenopause [6]. The Endocrine Society recommends TSH as a first-line screen in any patient with new-onset anxiety, tremor, or palpitations [7].

Complete Blood Count (CBC)

Iron-deficiency anemia causes fatigue, restlessness, irritability, and a sense of breathlessness that patients often describe as anxiety. A CBC with differential can detect anemia and also flag infection or hematologic abnormalities. Ferritin should be added if hemoglobin is borderline low, as iron stores can deplete before frank anemia appears [3].

Comprehensive Metabolic Panel (CMP)

The CMP covers electrolytes, glucose, calcium, and liver and kidney function. Hypoglycemia can trigger adrenergic symptoms (sweating, tremor, palpitations) identical to a panic attack. Hypercalcemia from hyperparathyroidism is another underdiagnosed cause of anxiety and cognitive fog. The CMP catches both [4].

Fasting Glucose and HbA1c

Reactive hypoglycemia, where blood sugar drops sharply 2-4 hours after a meal, is a common and overlooked driver of episodic anxiety. Fasting glucose paired with HbA1c can identify early insulin resistance or diabetes, both of which predispose to glycemic variability and mood symptoms [8].

Morning Cortisol

A morning cortisol level (drawn between 7:00 and 9:00 AM) screens for both cortisol excess (Cushing syndrome) and cortisol deficiency (adrenal insufficiency). Both extremes can present with anxiety, though through different mechanisms. Cushing syndrome produces a persistent anxious, wired state; adrenal insufficiency produces fatigue-driven anxiety and hypervigilance [9].

Second-Tier Labs: When to Go Deeper

Not every patient needs the tests below. Reserve them for cases where first-line labs are normal but clinical suspicion remains high, or where the patient profile suggests a specific etiology.

Catecholamines and Metanephrines

If anxiety is paroxysmal (sudden episodes of intense fear with hypertension and diaphoresis), plasma free metanephrines can rule out pheochromocytoma. This tumor is rare (2-8 per million per year), but missing it is dangerous [10].

Vitamin D, B12, and Folate

Vitamin D deficiency has been associated with anxiety in several observational studies, including a 2020 meta-analysis of 25 studies (N=7,534) published in the Journal of Affective Disorders that found significantly lower 25(OH)D levels in patients with anxiety compared to controls [11]. B12 and folate deficiency can impair methylation pathways involved in serotonin and dopamine synthesis. Testing is reasonable in vegetarians, older adults, and patients on metformin or proton pump inhibitors.

Sex Hormones

Estradiol, progesterone, total testosterone, free testosterone, and SHBG should be considered in women over 40 with new-onset anxiety (perimenopause is a known trigger) and in men with concurrent fatigue, low libido, or erectile dysfunction. The 2022 North American Menopause Society (NAMS) position statement acknowledges that the menopausal transition is associated with increased risk of anxiety and depressive symptoms, even in women with no prior psychiatric history [12].

Inflammatory Markers

High-sensitivity C-reactive protein (hs-CRP) and erythrocyte sedimentation rate (ESR) are not standard anxiety labs, but emerging research links systemic inflammation to anxiety. A 2019 Lancet Psychiatry meta-analysis (N=56,351) found that elevated CRP was associated with a 1.45-fold increased risk of anxiety disorders [13]. These markers may be useful in patients with comorbid autoimmune conditions or chronic pain.

Structured Screening: The GAD-7 and Beyond

Lab results tell you what anxiety is not. Structured screening tools tell you what it is.

The GAD-7

The Generalized Anxiety Disorder 7-item scale (GAD-7) is the most widely validated self-report measure for anxiety in primary care. A score of 0-4 indicates minimal anxiety, 5-9 mild, 10-14 moderate, and 15-21 severe. A score of 10 or higher has a sensitivity of 89% and specificity of 82% for generalized anxiety disorder [14]. The tool takes under two minutes to complete and is free to use.

PHQ-9 for Comorbid Depression

Anxiety and depression co-occur in roughly 60% of cases. The Patient Health Questionnaire-9 (PHQ-9) should be administered alongside the GAD-7 to screen for major depressive disorder. Dual diagnosis changes treatment selection: an SNRI like venlafaxine or duloxetine may be preferred over an SSRI when both conditions are present [15].

When Formal Psychiatric Evaluation Is Needed

Refer to psychiatry if: the patient has active suicidal ideation, psychotic features, bipolar symptoms, substance use disorder, or has failed two adequate trials of first-line medications. The APA Practice Guidelines for generalized anxiety disorder recommend psychiatric referral after two unsuccessful pharmacotherapy trials [16].

Evidence-Based Treatment: What Comes After the Labs

Once medical mimics are excluded, treatment follows a stepped-care model. Mild anxiety responds to lifestyle modification and psychotherapy alone. Moderate-to-severe anxiety typically requires medication, psychotherapy, or both.

Cognitive Behavioral Therapy (CBT)

CBT is the most studied psychotherapy for anxiety disorders. A 2018 Cochrane review of 41 randomized controlled trials (N=2,751) found that CBT significantly reduced anxiety symptoms compared to waitlist, with a standardized mean difference of -1.01 (95% CI: -1.30 to -0.73) [17]. Response rates in generalized anxiety disorder range from 45% to 55%, and gains are durable: most patients maintain improvement at 12-month follow-up.

CBT works by teaching patients to identify and restructure catastrophic thought patterns, then gradually expose themselves to feared situations. A typical course involves 12-16 weekly sessions.

SSRIs and SNRIs

The APA and the National Institute for Health and Care Excellence (NICE) both recommend selective serotonin reuptake inhibitors (SSRIs) as first-line pharmacotherapy for generalized anxiety disorder, social anxiety disorder, and panic disorder [16][18].

Sertraline (50-200 mg/day) and escitalopram (10-20 mg/day) are the most commonly prescribed SSRIs for anxiety. The STAR*D-adjacent trials and large observational datasets show anxiolytic response rates of approximately 50-60% with SSRIs [15]. SNRIs such as venlafaxine XR (75-225 mg/day) and duloxetine (60-120 mg/day) are equally effective and may be preferred in patients with comorbid chronic pain or depression.

Key prescribing points: start at low doses (half the target dose for the first week) to avoid a paradoxical spike in anxiety, warn patients that full effect takes 4-6 weeks, and plan for at least 12 months of continuous therapy before attempting a taper [16].

Buspirone

Buspirone (15-60 mg/day, divided BID-TID) is a 5-HT1A partial agonist approved for generalized anxiety disorder. It lacks the dependence risk of benzodiazepines and the sexual side effects common with SSRIs. A 2020 meta-analysis in the Journal of Clinical Psychopharmacology (9 RCTs, N=1,273) confirmed its efficacy over placebo with a moderate effect size (Hedges g = 0.39) [19]. Its main drawback is a slow onset (2-4 weeks) and the need for consistent dosing; it does not work PRN.

Benzodiazepines: A Limited Role

Benzodiazepines provide rapid anxiolysis but carry significant risks of tolerance, dependence, cognitive impairment, and falls in older adults. The APA recommends limiting benzodiazepine use to short-term bridging (2-4 weeks) while waiting for an SSRI to reach therapeutic effect, and only in patients without a history of substance use disorder [16]. Long-term benzodiazepine prescribing for anxiety is not supported by current evidence.

The Hormone Connection

Hormonal shifts are an underappreciated driver of anxiety, particularly in adults over 35.

Perimenopause and Anxiety

The menopausal transition produces erratic fluctuations in estradiol and progesterone that directly affect GABAergic and serotonergic neurotransmission. The Penn Ovarian Aging Study, a longitudinal cohort of 436 women, found that the odds of anxiety increased 2.7-fold during perimenopause compared to premenopause, independent of hot flashes and sleep disruption [20]. Progesterone metabolites (particularly allopregnanolone) are potent GABA-A receptor modulators, and their decline during perimenopause may contribute to the anxiogenic effect.

For perimenopausal women with anxiety that began during the transition, hormone therapy (estradiol plus micronized progesterone) may be a reasonable adjunct. The 2022 NAMS position statement supports this approach when vasomotor symptoms and mood symptoms co-occur [12].

Low Testosterone and Anxiety in Men

Testosterone has anxiolytic properties mediated through androgen receptors in the amygdala and hippocampus. A cross-sectional analysis from the European Male Aging Study (N=3,369) found that men with total testosterone below 8 nmol/L had significantly higher scores on anxiety measures compared to men with levels above 15 nmol/L [21]. Testosterone replacement therapy (TRT) is not FDA-approved for anxiety, but treating confirmed hypogonadism may improve anxiety symptoms as a secondary benefit.

Building Your Anxiety Action Plan

A structured approach prevents both overdiagnosis (treating normal worry as a disorder) and underdiagnosis (missing a thyroid problem for years).

Step 1: Get the Labs

Request the core panel: TSH, free T4, CBC, CMP, fasting glucose, HbA1c, morning cortisol. Add sex hormones, vitamin D, B12, and folate if the clinical picture suggests hormonal or nutritional involvement.

Step 2: Complete a GAD-7

Score your symptoms honestly. A score of 10 or higher warrants a conversation with your clinician about treatment options. Track your score monthly to monitor response.

Step 3: Address Modifiable Factors

Regular aerobic exercise (150 minutes per week of moderate-intensity activity) has demonstrated anxiolytic effects comparable to low-dose SSRIs in a 2021 BMJ meta-analysis of 97 reviews [22]. Caffeine intake above 400 mg/day can exacerbate anxiety. Alcohol, often used as self-medication, worsens anxiety through rebound GABA withdrawal.

Step 4: Start Evidence-Based Treatment

If GAD-7 remains at 10 or above after 4 weeks of lifestyle changes, initiate CBT, pharmacotherapy, or both. Discuss preferences and side-effect profiles with your prescriber. Schedule a follow-up at 4-6 weeks to assess response.

Patients who do not respond to two adequate medication trials (each at therapeutic dose for at least 8 weeks) should be referred for psychiatric evaluation to reassess the diagnosis and consider augmentation strategies such as adding buspirone to an SSRI or switching to an SNRI [16].